NCT01381562 - GSK2251052 in the Treatment of Complicated Intra-abdominal Infections | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2011

Primary Completion Date

March 5, 2012

Study Completion Date

March 5, 2012

Conditions

Infections, Intestinal

Interventions

DRUG

Drug: GSK2251052

Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion

DRUG

Meropenem

Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion

OTHER

Placebo

saline placebo

Trial Locations (31)

10034

GSK Investigational Site, Prague

14215

GSK Investigational Site, Buffalo

23298

GSK Investigational Site, Richmond

28006

GSK Investigational Site, Madrid

30029

GSK Investigational Site, Nîmes

32209

GSK Investigational Site, Jacksonville

36617

GSK Investigational Site, Mobile

37134

GSK Investigational Site, Verona

43215

GSK Investigational Site, Columbus

45801

GSK Investigational Site, Lima

51503

GSK Investigational Site, Council Bluffs

66604

GSK Investigational Site, Topeka

67200

GSK Investigational Site, Strasbourg

70112

GSK Investigational Site, New Orleans

87042

GSK Investigational Site, Limoges

89109

GSK Investigational Site, Las Vegas

90509

GSK Investigational Site, Torrance

90822

GSK Investigational Site, Long Beach

192242

GSK Investigational Site, Saint Petersburgh

214019

GSK Investigational Site, Smolensk

614036

GSK Investigational Site, Perm

614068

GSK Investigational Site, Perm

664079

GSK Investigational Site, Irkutsk

G7H 5H6

GSK Investigational Site, Chicoutimi

J1H 5N4

GSK Investigational Site, Sherbrooke

G8Z 3R9

GSK Investigational Site, Trois-Rivières

S7N 0W8

GSK Investigational Site, Saskatoon

100 34

GSK Investigational Site, Prague

03010

GSK Investigational Site, Alicante

03203

GSK Investigational Site, Elche (Alicante)

07010

GSK Investigational Site, Pama de Mallorca